Singapore-Based CytoMed Therapeutics Stock Dips After SunAct Joins Clinical Trial As Joint Sponsor
CytoMed's stock dropped 6.35% to $3.23. Collaboration with SunAct Cancer Institute to explore gamma delta T cell therapy. The agreement involves a Phase 2 clinical trial for various cancers in India. Trial aims to assess safety, efficacy, and optimal dosing of the therapy. CytoMed will manufacture the investigational product for the clinical trial.
View signal analysis